Kymab has hired on a new CEO, Simon Sturge, to usher the antibody specialist into its next phase of growth. Sturge joins from Merck KGaA, where as an executive vice president he oversaw business development and global strategy and operations. Sturge will take over from David Chiswell, who has been steering the ship since 2015, first as interim CEO before taking on the post full-time. Source: Fierce Biotech 8/4/2019